Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZELNORM

Summary for Tradename: ZELNORM

patent expirations by year for

Clinical Trials for: ZELNORM

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
Status: No longer available Condition: Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
Status: Terminated Condition: Gastroparesis; Diabetes

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Status: Terminated Condition: Opioid-induced Constipation

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Status: Terminated Condition: Opioid-induced Constipation

The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
Status: Completed Condition: Heartburn; Dyspepsia

The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
Status: Withdrawn Condition: Constipation and Dyspepsia

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Status: Completed Condition: Constipation

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation
Status: Completed Condition: Chronic Constipation

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.
Status: Completed Condition: Chronic Constipation

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Status: Completed Condition: Gastroesophageal Reflux Disease (GERD)

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
tegaserod maleate
TABLET;ORAL021200Jul 24, 2002DISCNNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology